Current Liabilities decreased faster than Elite Pharmaceuticals Inc 's Cash & cash equivalent, this led to improvement in Elite Pharmaceuticals Inc 's Quick Ratio to 1.92, above Elite Pharmaceuticals Inc average Quick Ratio.

Within Major Pharmaceutical Preparations industry 353 other companies have achieved higher Quick Ratio than Elite Pharmaceuticals Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 1633 to 2100.

Explain Quick Ratio?
How much Cash & cash equivalents ELTP�s has?
What are ELTP�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/ELTP/financial-strength

https://api.csimarket.com/api/v1/companies/ELTP/fundamentals

https://api.csimarket.com/api/v1/companies/ELTP/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

ELTP Quick Ratio	(Sep 30 2026) Q2	(Jun 30 2026) Q1	(Mar 31 2026) Q4	(Dec 31 2025) Q3	(Sep 30 2025) Q2
Y / Y Current Liabilities Change	-64.03 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	30.25 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	1.92	Subscribe	Subscribe	Subscribe	Subscribe
ELTP's Total Ranking	# 2100	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	-40.37 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	-10.68 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio second quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 354
Healthcare Sector	# 642
Overall Market	# 2100

Quick Ratio Statistics
High	Average	Low
3.18	1.08	0.05
(Dec 31 2017)		(Sep 30 2012)

Financial Statements
Elite Pharmaceuticals Inc 's Current Liabilities	$ 18 Millions	Visit ELTP's Balance sheet
Elite Pharmaceuticals Inc 's Cash & cash equivalent	$ 35 Millions	Visit ELTP's Balance sheet
Source of ELTP's Sales		Visit ELTP's Sales by Geography

Cumulative Elite Pharmaceuticals Inc 's Quick Ratio

ELTP's Quick Ratio for the trailling 12 Months

ELTP Quick Ratio	(Sep 30 2026) 12 Months	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	-28.62 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	82.85 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	1.3	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 4513	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	-25.1 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	6.93 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to ELTP Financial Strength Comparisons >> Go to Compare ELTP Quick Ratio to its Competitors

On the trailing twelve months basis ELTP Cash & cash equivalent grew by 30.25 % in Q2 2026 year on year, while Current Liabilities plummeted to $18 millions, this led to increase in in Elite Pharmaceuticals Inc 's Quick Ratio to 1.3, above ELTP average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 483 other companies have achieved higher Quick Ratio than Elite Pharmaceuticals Inc . While Quick Ratio overall ranking has improved so far to 4513, from total ranking during the twelve months ending first quarter 2026 at 4561.

Explain Quick Ratio?
How much Cash & cash equivalents ELTP�s has?
What are ELTP�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 484
Healthcare Sector	# 988
Within the Market	# 4513

trailing twelve months Quick Ratio Statistics
High	Average	Low
2.78	1.12	0.06
(Dec 31 2017)		(Dec 31 2013)

Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Sep 30 2026 MRQ Cash & cash equivalent	Sep 30 2026 MRQ Current Liabilities
Rocket Pharmaceuticals Inc	5.22	$ 279.470 Millions	$ 53.508 Millions
Aquestive Therapeutics Inc	5.22	$ 90.349 Millions	$ 17.299 Millions
Sionna Therapeutics Inc	5.11	$ 83.878 Millions	$ 16.420 Millions
Gain Therapeutics inc	4.94	$ 11.698 Millions	$ 2.369 Millions
Rani Therapeutics Holdings Inc	4.91	$ 45.288 Millions	$ 9.223 Millions
Abeona Therapeutics Inc	4.87	$ 134.941 Millions	$ 27.707 Millions
Shattuck Labs Inc	4.84	$ 61.758 Millions	$ 12.758 Millions
Mereo Biopharma Group Plc	4.75	$ 26.097 Millions	$ 5.494 Millions
Spruce Biosciences Inc	4.69	$ 87.691 Millions	$ 18.710 Millions
Diamedica Therapeutics Inc	4.68	$ 34.905 Millions	$ 7.454 Millions
Eledon Pharmaceuticals Inc	4.61	$ 69.672 Millions	$ 15.099 Millions
Septerna Inc	4.56	$ 478.601 Millions	$ 104.863 Millions
Atossa Therapeutics Inc	4.37	$ 20.574 Millions	$ 4.709 Millions
Adial Pharmaceuticals Inc	4.35	$ 22.000 Millions	$ 5.056 Millions
Neurogene Inc	4.35	$ 78.942 Millions	$ 18.163 Millions
Entrada Therapeutics Inc	4.34	$ 112.302 Millions	$ 25.863 Millions
Gyre Therapeutics Inc	4.34	$ 86.190 Millions	$ 19.874 Millions
Serina Therapeutics Inc	4.28	$ 19.403 Millions	$ 4.529 Millions
Cellectar Biosciences Inc	4.24	$ 24.582 Millions	$ 5.798 Millions
Bio Green Med Solution Inc	4.24	$ 3.454 Millions	$ 0.815 Millions
Foghorn Therapeutics Inc	4.19	$ 156.222 Millions	$ 37.315 Millions
Calcimedica Inc	4.12	$ 13.768 Millions	$ 3.339 Millions
Revelation Biosciences Inc	3.92	$ 9.122 Millions	$ 2.328 Millions
Tonix Pharmaceuticals Holding Corp	3.87	$ 162.793 Millions	$ 42.026 Millions
Lyell Immunopharma Inc	3.83	$ 177.106 Millions	$ 46.271 Millions
Rapport Therapeutics Inc	3.68	$ 74.754 Millions	$ 20.302 Millions
Seaport Therapeutics Inc	3.60	$ 61.552 Millions	$ 17.106 Millions
Xilio Therapeutics Inc	3.47	$ 122.182 Millions	$ 35.258 Millions
Corbus Pharmaceuticals Holdings Inc	3.30	$ 115.337 Millions	$ 34.967 Millions
Maia Biotechnology Inc	3.30	$ 21.339 Millions	$ 6.474 Millions

Date modified: 2026-11-13T21:15:37+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.